Grant Langdon

Saffron Walden, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.

Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: April 08, 2025

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.

Journal: The American journal of tropical medicine and hygiene

Published: September 09, 2020

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Journal: Blood advances

Published: April 06, 2020

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers.

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers.

Journal: Antimicrobial agents and chemotherapy

Published: September 30, 2019

First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection.

First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection.

Journal: British journal of clinical pharmacology

Published: July 19, 2019

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.

The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.

Journal: Science translational medicine

Published: March 07, 2017

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.

Journal: Antiviral therapy

Published: December 23, 2012

The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.

The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: April 21, 2012

The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.

The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.

Journal: European journal of clinical pharmacology

Published: December 02, 2011

Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.

Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.

Journal: Antimicrobial agents and chemotherapy

Published: November 30, 2011

Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.

Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.

Journal: British journal of clinical pharmacology

Published: November 02, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026